These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 32146731)

  • 21. Adult IDH wild-type lower-grade gliomas should be further stratified.
    Aibaidula A; Chan AK; Shi Z; Li Y; Zhang R; Yang R; Li KK; Chung NY; Yao Y; Zhou L; Wu J; Chen H; Ng HK
    Neuro Oncol; 2017 Oct; 19(10):1327-1337. PubMed ID: 28575485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.
    Diplas BH; He X; Brosnan-Cashman JA; Liu H; Chen LH; Wang Z; Moure CJ; Killela PJ; Loriaux DB; Lipp ES; Greer PK; Yang R; Rizzo AJ; Rodriguez FJ; Friedman AH; Friedman HS; Wang S; He Y; McLendon RE; Bigner DD; Jiao Y; Waitkus MS; Meeker AK; Yan H
    Nat Commun; 2018 May; 9(1):2087. PubMed ID: 29802247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The correlation analysis of TERT promoter mutations with IDH1/2 mutations and 1p/19q detected in human gliomas.
    Xu J; Xu FP; Liu ZH; Cui Q; Zhang KP; Li Z
    Medicine (Baltimore); 2022 Jul; 101(29):e29668. PubMed ID: 35866817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prognostic significance of combined TERT and IDH gene mutation analysis in diffusely infiltrating gliomas].
    Liu QQ; Yin XX; Zou Y; Yu TP; Gong J; Chen XQ; Nie L; Xu M; Zhang MN; Zhou Q; Chen N
    Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):658-663. PubMed ID: 30220117
    [No Abstract]   [Full Text] [Related]  

  • 25. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.
    Chan AK; Yao Y; Zhang Z; Chung NY; Liu JS; Li KK; Shi Z; Chan DT; Poon WS; Zhou L; Ng HK
    Mod Pathol; 2015 Feb; 28(2):177-86. PubMed ID: 25081751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Place and Prognostic Value of TERT Promoter Mutation in Molecular Classification in Grade II-III Glial Tumors and Primary Glioblastomas.
    Terzi NK; Yilmaz I; Oz AB
    Turk Patoloji Derg; 2022; 38(2):90-98. PubMed ID: 34558656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Telomerase Reverse Transcriptase Promoter Mutations in A Cohort Of Adult Gliomas - Clinicopathological Correlates.
    Balakumar S; Pai R; Chacko AG; Patel B; Nancy R; Balakrishnan R; Sarkar S; Sampath G; Chacko G
    Neurol India; 2022; 70(3):953-959. PubMed ID: 35864624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TERT Promoter Mutation Analysis to Distinguish Glioma From Gliosis.
    Hewer E; Phour J; Gutt-Will M; Schucht P; Dettmer MS; Vassella E
    J Neuropathol Exp Neurol; 2020 Apr; 79(4):430-436. PubMed ID: 32068851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinicopathological and molecular genetic characteristics of adult IDH wild-type diffuse gliomas].
    Wang LM; Wang W; Liu L; Gao M; Yao YY; Zhang M; Xiong YL; Shao Y; Lu DH; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2021 Jul; 50(7):734-739. PubMed ID: 34405606
    [No Abstract]   [Full Text] [Related]  

  • 30.
    Juratli TA; Stasik S; Zolal A; Schuster C; Richter S; Daubner D; Juratli MA; Thowe R; Hennig S; Makina M; Meinhardt M; Lautenschlaeger T; Schackert G; Krex D; Thiede C
    Clin Cancer Res; 2018 Nov; 24(21):5282-5291. PubMed ID: 29941484
    [No Abstract]   [Full Text] [Related]  

  • 31. Highly sensitive detection of TERT promoter mutations in recurrent glioblastomas using digital PCR.
    Miki S; Satomi K; Ohno M; Matsushita Y; Kitahara M; Miyakita Y; Takahashi M; Matsuda M; Ishikawa E; Matsumura A; Yoshida A; Narita Y; Ichimura K
    Brain Tumor Pathol; 2020 Oct; 37(4):154-158. PubMed ID: 32749624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism.
    Batista R; Cruvinel-Carloni A; Vinagre J; Peixoto J; Catarino TA; Campanella NC; Menezes W; Becker AP; de Almeida GC; Matsushita MM; Clara C; Neder L; Viana-Pereira M; Honavar M; Castro L; Lopes JM; Carvalho B; Vaz RM; Máximo V; Soares P; Sobrinho-Simões M; Reis RM; Lima J
    Int J Cancer; 2016 Jul; 139(2):414-23. PubMed ID: 26914704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting.
    Hewer E; Prebil N; Berezowska S; Gutt-Will M; Schucht P; Dettmer MS; Vassella E
    Virchows Arch; 2017 Nov; 471(5):641-649. PubMed ID: 28823044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic Performance of [
    Nakajo K; Uda T; Kawashima T; Terakawa Y; Ishibashi K; Tsuyuguchi N; Tanoue Y; Nagahama A; Uda H; Koh S; Sasaki T; Ohata K; Kanemura Y; Goto T
    World Neurosurg; 2021 Apr; 148():e471-e481. PubMed ID: 33444827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II/III gliomas: A prospective randomized study.
    Qiu X; Chen Y; Bao Z; Chen L; Jiang T
    Radiother Oncol; 2022 Feb; 167():1-6. PubMed ID: 34902368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
    Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
    J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination genetic signature stratifies lower-grade gliomas better than histological grade.
    Chan AK; Yao Y; Zhang Z; Shi Z; Chen L; Chung NY; Liu JS; Li KK; Chan DT; Poon WS; Wang Y; Zhou L; Ng HK
    Oncotarget; 2015 Aug; 6(25):20885-901. PubMed ID: 26369702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.
    Eckel-Passow JE; Lachance DH; Molinaro AM; Walsh KM; Decker PA; Sicotte H; Pekmezci M; Rice T; Kosel ML; Smirnov IV; Sarkar G; Caron AA; Kollmeyer TM; Praska CE; Chada AR; Halder C; Hansen HM; McCoy LS; Bracci PM; Marshall R; Zheng S; Reis GF; Pico AR; O'Neill BP; Buckner JC; Giannini C; Huse JT; Perry A; Tihan T; Berger MS; Chang SM; Prados MD; Wiemels J; Wiencke JK; Wrensch MR; Jenkins RB
    N Engl J Med; 2015 Jun; 372(26):2499-508. PubMed ID: 26061753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paradoxical prognostic impact of TERT promoter mutations in gliomas depends on different histological and genetic backgrounds.
    You H; Wu Y; Chang K; Shi X; Chen XD; Yan W; Li R
    CNS Neurosci Ther; 2017 Oct; 23(10):790-797. PubMed ID: 28868656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.